Eric Karas's most recent trade in ARS Pharmaceuticals Inc was a trade of 15,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2025 | 15,000 | 544,588 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Karas Eric | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 16.99 per share. | 01 Jul 2025 | 15,000 | 10,315 | - | 17.0 | 254,861 | Common Stock |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 01 Jul 2025 | 15,000 | 25,315 | - | 1.5 | 22,500 | Common Stock |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 18 Jun 2025 | 15,000 | 22,696 | - | 1.5 | 22,500 | Common Stock |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 18 Jun 2025 | 15,000 | 7,696 | - | 16 | 240,000 | Common Stock |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 15,000 | 559,588 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 20 Mar 2025 | 10,000 | 17,696 | - | 1.5 | 15,000 | Common Stock |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2025 | 10,000 | 574,588 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 20 Mar 2025 | 10,000 | 7,696 | - | 14 | 140,000 | Common Stock |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 152,300 | 152,300 | - | - | Stock option (right to buy) | |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 02 Dec 2024 | 6,283 | 11,976 | - | 1.5 | 9,425 | Common Stock |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 6,283 | 584,588 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 02 Dec 2024 | 6,283 | 5,693 | - | 14 | 87,962 | Common Stock |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 3,717 | 590,871 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 14.11 per share. | 02 Dec 2024 | 3,717 | 5,693 | - | 14.1 | 52,461 | Common Stock |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 02 Dec 2024 | 3,717 | 9,410 | - | 1.5 | 5,576 | Common Stock |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 18 Sep 2024 | 10,000 | 15,693 | - | 1.5 | 15,000 | Common Stock |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2024 | 10,000 | 594,588 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 18 Sep 2024 | 10,000 | 5,693 | - | 14 | 140,000 | Common Stock |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 19 Aug 2024 | 10,000 | 15,693 | - | 1.5 | 15,000 | Common Stock |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 19 Aug 2024 | 10,000 | 5,693 | - | 14 | 140,000 | Common Stock |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 10,000 | 604,588 | - | - | Stock Option (Right to Buy) | |
| ARS Pharmaceuticals Inc | Karas Eric | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 200,000 | 200,000 | - | - | Stock option (right to buy) | |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 50,000 | 50,000 | - | - | Stock option (right to buy) | |
| ARS Pharmaceuticals Inc | Eric Karas | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2022 | 614,588 | 614,588 | - | - | Stock option (right to buy) |